Sernova Biotherapeutics FY26 Q3 net loss narrows 37.91% to CAD 2.53 million

Reuters2026/09/11 14:59

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sernova Biotherapeutics posted a Q3 net loss of CAD 2.53 million, narrowing 37.91% from a year earlier.
Loss per share held at CAD 0.01; operating expenses fell 39.49% to CAD 2.12 million on lower research and development spending.
Finance costs dropped 51.97% to CAD 260,183, while foreign exchange losses widened to CAD 196,273 from CAD 62,179.
Nine-month net loss narrowed 40.27% to CAD 8.09 million, helped by a 48.38% decline in operating expenses to CAD 6.53 million.
Cash ended at CAD 63,331; September merger deal signed with Seraxis to form BetaNova, backed by US$10 million convertible note commitments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sernova Biotherapeutics Inc. published the original content used to generate this news brief on September 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Sernova Biotherapeutics FY26 Q3 net loss narrows 37.91% to CAD 2.53 million

You may also like

Crypto prices